Theseus Pharmaceuticals (Theseus Pharmaceuticals) Operating Income : $-66.52 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Theseus Pharmaceuticals Operating Income?

Theseus Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $-16.40 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-66.52 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Theseus Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $-16.40 Mil. Theseus Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Theseus Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2023 was %.

Theseus Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Theseus Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2023 was -207.32%. Theseus Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -1,485.95%.

Theseus Pharmaceuticals Operating Income Historical Data

The historical data trend for Theseus Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theseus Pharmaceuticals Operating Income Chart

Theseus Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Operating Income

-4.94

-6.84

-27.34

-54.09

Theseus Pharmaceuticals Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Operating Income	Get a 7-Day Free Trial										-15.95	-15.48	-17.06	-17.59	-16.40

Theseus Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.52 Mil.

Theseus Pharmaceuticals (NAS:THRX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Theseus Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-65.612 * ( 1 - 0% )	/	( (34.309	+	28.987)	/ 2 )
=	-65.612	/	31.648
=	-207.32 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	245.071	-	4.691	-	( 208.205	-	max(0, 7.682	-	213.753	+	208.205	))
=	34.309

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	234.627	-	3.057	-	( 205.122	-	max(0, 7.003	-	209.586	+	205.122	))
=	28.987

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Theseus Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-65.612	/	( ( (4.497 + max(-1.38, 0))	+	(4.334 + max(-1.78, 0)) )	/	2 )
=	-65.612	/	( ( 4.497	+	4.334 )	/	2 )
=	-65.612	/	4.4155
=	-1,485.95 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	5.548)	-	(4.691	+	0	+	2.237)
=	-1.38

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.464)	-	(3.057	+	0	+	3.187)
=	-1.78

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Theseus Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-16.403	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Theseus Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of Theseus Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Theseus Pharmaceuticals (Theseus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theseus Pharmaceuticals Inc (NAS:THRX) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 Main Street, Cambridge, MA, USA, 02142

Website

https://www.theseusrx.com

Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Foresite Capital Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Hayden Donald J Jr	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradford D. Dahms	officer: Chief Financial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Timothy P Clackson	director, officer: President and CEO	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Steven H Stein	director	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Foresite Capital Opportunity Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Opportunity Fund V, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management V, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
James B. Tananbaum	10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
William Shakespeare	officer: See Remarks	245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142
Rock Springs Capital Master Fund Lp	10 percent owner	190 ELGIN AVENUE, GEORGE TOWN E9 KY1 9001
Omega Fund Vi Gp Manager, Ltd.	10 percent owner	888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199
Orbimed Capital Gp Vii Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022